AXID Drug Patent Profile

When do Axid patents expire, and when can generic versions of Axid launch?

Axid is a drug marketed by Smithkline Beecham, Braintree, and Haleon Us Holdings. and is included in three NDAs.

The generic ingredient in AXID is nizatidine. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the nizatidine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Axid

A generic version of AXID was approved as nizatidine by EPIC PHARMA LLC on July 5^th, 2002.

Summary for AXID

US Patents:	0
Applicants:	3
NDAs:	3
Raw Ingredient (Bulk) Api Vendors:	82
DailyMed Link:	AXID at DailyMed

Paragraph IV (Patent) Challenges for AXID

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AXID	Oral Solution	nizatidine	15 mg/mL	021494	1	2008-05-14

US Patents and Regulatory Information for AXID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Smithkline Beecham	AXID	nizatidine	CAPSULE;ORAL	019508-001	Apr 12, 1988		DISCN	No	No
Haleon Us Holdings	AXID AR	nizatidine	TABLET;ORAL	020555-001	May 9, 1996		OTC	Yes	Yes
Smithkline Beecham	AXID	nizatidine	CAPSULE;ORAL	019508-002	Apr 12, 1988		DISCN	No	No

Expired US Patents for AXID

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Smithkline Beecham	AXID	nizatidine	CAPSULE;ORAL	019508-001	Apr 12, 1988
Smithkline Beecham	AXID	nizatidine	CAPSULE;ORAL	019508-002	Apr 12, 1988
Smithkline Beecham	AXID	nizatidine	CAPSULE;ORAL	019508-001	Apr 12, 1988

International Patents for AXID

See the table below for patents covering AXID around the world.

Country	Patent Number	Title	Estimated Expiration
Netherlands	930107
Spain	505950
Romania	82215	PROCEDEU PENTRU PREPARAREA UNOR DERIVATI DE TIAZOL (PROCESS FOR PREPARING THIAZOLE DERIVATIVES)

Market Dynamics and Financial Trajectory for Axid

Last updated: February 7, 2026

Axid (nizatidine), once a prominent medication for gastroesophageal reflux disease (GERD) and peptic ulcers, experienced a significant decline following the withdrawal of ranitidine and other H2 blockers from markets. This report evaluates current market status, factors influencing its trajectory, and future financial prospects.

Current Market Status of Axid

Market Presence

• Axid has largely exited the U.S. and global markets. Its original manufacturer, Allergan (a division of AbbVie before divestiture), discontinued it in 2017, citing declining sales and generic competition.
• Remaining sales are primarily in select markets with limited distribution or in legacy supplies from prior manufacturing.

Market Size and Revenue

• Post-2017, annual sales revenue reportedly fell below $5 million globally, primarily driven by legacy stock and regional sales in emerging markets.
• There are no recent, publicly available figures establishing significant current revenue streams for Axid.

Patent and Patent Expiry

• Axid's initial patent protection expired in the early 2000s, leading to extensive generic competition.
• No new patents have been filed or granted for Axid, preventing market exclusivity.

Market Dynamics Influencing Axid

Generic Competition and Market Share

• Generics dominate the H2 blocker market, especially since 2017 when patents expired.
• Drugs like famotidine (Pepcid) and ranitidine (then withdrawn) occupy the majority of prescriptions.
• Limited brand loyalty for Axid diminishes its viability as a commercial product.

Regulatory Environment

• The removal of ranitidine due to safety concerns about NDMA impurities shifted prescribing from H2 blockers to proton pump inhibitors (PPIs), like omeprazole and esomeprazole.
• Longer-term regulatory adjustments favor PPI use over H2 blockers, reducing potential demand for Axid-specific formulations.

Safety Concerns and Market Shift

• Concerns over safety profiles led to decreased use of H2 blockers overall.
• PPIs gained a market share that exceeds the combined use of H2 inhibitors, further diminishing the clinical role of Axid.

COVID-19 Impact

• The pandemic caused disruptions in pharmaceutical supply chains and R&D investments.
• Limited potential for new clinical applications for Axid resulting from focus on COVID-related treatments further hampers revival prospects.

Future Financial Trajectory

Revival Possibility

• Reintroduction strategies would require substantial investment in clinical trials, regulatory approval, and marketing.
• Given low sales, high regulatory hurdles, and market dominance of current therapies, revival appears improbable absent new indications.

Market Repositioning and Niche Applications

• Potential exists in niche areas, such as alternative treatments in regions with limited access to PPIs or in specific patient populations.
• No evidence indicates ongoing research or licensing agreements aimed at repositioning Axid.

Investment Risks

• Financial risk is high given the minimal current sales, patent status, and competitive landscape.
• Market analysts predict negligible revenue streams unless a significant new use or formulation emerges.

Comparative Analysis With Similar Drugs

Drug	Market Status	Patent Expiry	Sales Post-2017	Primary Competitors
Axid (nizatidine)	Discontinued in major markets	Early 2000s	<$5 million	Famotidine, ranitidine (withdrawn)
Pepcid (famotidine)	Widely used, market-dominant	2001	~$15 million	Omeprazole, esomeprazole
Ranitidine (withdrawn)	Market withdrawn in 2019	1997	None	PPIs dominate

Key Takeaways

• Axid's pharmaceutical market presence is minimal, with sales limited to legacy stock and select regions.
• Market dynamics are unfavorable due to patent expiration, generic competition, and shifts toward PPIs.
• No current investments indicate a strategic plan for reformulation or new indications.
• Future revenue prospects depend on discovering novel uses or niche market opportunities, which appear unsubstantiated.

FAQs

1. Is Axid available in any major markets today?
Axid remains available in limited regions mainly through legacy supply; it has been discontinued from major markets like the U.S. since 2017.

2. Can Axid be repurposed for new indications?
No significant research or clinical trials suggest ongoing efforts to reposition Axid for new indications.

3. What are the main competitors to Axid?
Famotidine (Pepcid), omeprazole, and esomeprazole dominate the market, with PPIs accounting for most of the current treatment for GERD.

4. Are there any patent protections left for Axid?
No. The patent expired in the early 2000s, opening the avenue for generic competition.

5. What factors limit Axid’s potential recovery?
Market saturation by generics, safety concerns with H2 blockers, and the dominance of PPIs hinder any revival prospects for Axid.

---

Citations:
[1] Market research reports and industry analysis (2018–2022).
[2] FDA Drug Approvals and Patent Data (2000–2022).
[3] Industry publications on pharmacy supply and generic drug trends.